Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance

Gilead Sciences, Inc.Trade
Vanguard High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Vanguard High Dividend Yield ETF — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Vanguard High Dividend Yield ETF trades at $166.68. The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Vanguard High Dividend Yield ETF pays none, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

GILDVYM
Market Cap
$164.99B
Sector
Health
52-Week High
$155.80$166.14
52-Week Low
$110.56$136.63
Enterprise Value
$188.06B
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

No Aura AI signal available yet.

Vanguard High Dividend Yield ETF

VYM trades at $165.63, up 0.52% today, near its 52-week high with strong bullish momentum from moving averages. The ETF's technicals show overbought RSI signals but positive ADX trends, while recent news highlights its role in retirement income strategies. A dividend of $0.98 is scheduled for June 2026, reinforcing its income focus amid institutional adjustments.

Outlook remains positive for income-seeking investors due to VYM's dividend reliability and sector diversification, though overbought conditions and underperformance versus the S&P 500 pose risks. Key opportunities include sustainable yield; risks involve market volatility and interest rate sensitivity.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Vanguard High Dividend Yield ETF

The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VYM